Document is current
Any future updates will be listed below
-
Authors
Nagano, China https://orcid.org/0000-0003-4946-1345
Morisada, Naoya
Inoki, Yuta
Tanaka, Yu
Ichikawa, Yuta
Ueda, Chika
Kitakado, Hideaki
Aoto, Yuya
Sakakibara, Nana
Horinouchi, Tomoko
Yamamura, Tomohiko
Ishimori, Shingo
Nozu, Kandai
-
Funding
Funding for this research was provided by:
Grants-in-Aid for Scientific Research (23K07698)
Health, Labour and Welfare Sciences Research Grants (23FC1047)
Health Labor Sciences Research Grant (H29-nanchi-ippan-039, 23FC1047)
Japan Society for the Promotion of Science (JP15K09261, 18K08243, 22K08351)
Kobe University
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 3 April 2025
First Online: 17 April 2025
Declarations
:
: Kandai Nozu is a member of advisory groups for Kyowa Kirin Co. Ltd., Toa Eiyo Ltd., Zenyaku Kogyo Co. Ltd., and Taisho Pharmaceutical Co. Ltd. Kandai Nozu received lecture fees from Ono Pharma, Astellas Pharma, Novo Nordisk Pharma, Alexion Pharma, Sumitomo Pharma, Sanofi, Otsuka Pharma, Daiichi Sankyo, and Miyarisan. Kandai Nozu received grants from Zenyaku Kogyo and Torii Co. Ltd. Kandai Nozu received a patent for an exon skipping therapy for Alport syndrome. Tomoko Horinouchi received research funding from Otsuka Pharmaceutical Co., Ltd., Sysmex Corporation, and Zenyaku Kogyo Co., Ltd. All the other authors have nothing to disclose.
: All the procedures involving human participants were performed in accordance with the ethical standards of the Institutional Review Board of Kobe University Graduate School of Medicine (IRB approval number 301) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
: Informed consent was obtained from all individual participants included in the study.
